[go: up one dir, main page]

BR0005633A - Derivados de quinolina úteis para inibição da farnesil proteìna transferase - Google Patents

Derivados de quinolina úteis para inibição da farnesil proteìna transferase

Info

Publication number
BR0005633A
BR0005633A BR0005633-2A BR0005633A BR0005633A BR 0005633 A BR0005633 A BR 0005633A BR 0005633 A BR0005633 A BR 0005633A BR 0005633 A BR0005633 A BR 0005633A
Authority
BR
Brazil
Prior art keywords
protein transferase
farnesyl protein
compounds
derivatives useful
quinoline derivatives
Prior art date
Application number
BR0005633-2A
Other languages
English (en)
Inventor
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0005633A publication Critical patent/BR0005633A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE QUINOLINA úTEIS PARA INIBIçãO DA FARNESIL PROTEìNA TRANSFERASE"<D>. A invenção refere-se a compostos da fórmula: e a sais farmaceuticamente aceitáveis derivados e solvatos resultantes em que Y, R¹, R², R³, R^ 4^, R^ 5^, R^ 6^, R^ 7^, R^ 8^, R^ 9^, e R^ 10^ têm os significados definidos na especificação. A invenção também refere-se a composições farmacêuticas compreendendo os ditos compostos e ao uso dos ditos compostos para inibição do crescimento celular anormal em mamíferos. Os compostos da forma acima descrita têm atividade como inibidores da farnesil proteína transferase.
BR0005633-2A 1999-11-30 2000-11-30 Derivados de quinolina úteis para inibição da farnesil proteìna transferase BR0005633A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16820799P 1999-11-30 1999-11-30
US17011999P 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
BR0005633A true BR0005633A (pt) 2001-07-17

Family

ID=26863889

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0005633-2A BR0005633A (pt) 1999-11-30 2000-11-30 Derivados de quinolina úteis para inibição da farnesil proteìna transferase

Country Status (12)

Country Link
US (1) US6596735B1 (pt)
EP (1) EP1106612B1 (pt)
JP (1) JP2001213876A (pt)
AT (1) ATE259365T1 (pt)
BR (1) BR0005633A (pt)
CA (1) CA2327026A1 (pt)
DE (1) DE60008206T2 (pt)
DK (1) DK1106612T3 (pt)
ES (1) ES2212971T3 (pt)
MX (1) MXPA00011856A (pt)
PT (1) PT1106612E (pt)
TR (1) TR200400342T4 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
AU2001293826A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
CA2510850A1 (en) 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
US7517890B2 (en) 2003-11-20 2009-04-14 Children's Hospital Medical Center GTPase inhibitors and methods of use
CA2547518A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
ME01788B (me) * 2004-08-26 2011-02-28 Pfizer Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
GEP20094845B (en) * 2004-08-26 2009-11-25 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
EP1920048A4 (en) 2005-07-29 2009-12-09 Childrens Hosp Medical Center GTASE INHIBITORS AND USE METHOD AND CRYSTAL STRUCTURE OF RAC-1 GTASE
EP1933871B1 (en) 2005-09-07 2013-04-24 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MY150756A (en) 2006-08-21 2014-02-28 Hoffmann La Roche Tumor theraphy with an anti-vegf antibody
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011093365A1 (ja) * 2010-01-27 2011-08-04 協和発酵キリン株式会社 含窒素複素環化合物
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
PE20151203A1 (es) 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
HK1213250A1 (zh) 2012-10-16 2016-06-30 Janssen Pharmaceutica, N.V. RORγT的雜芳基連接的喹啉基調節劑
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
JP6877429B2 (ja) 2015-12-03 2021-05-26 アジオス ファーマシューティカルズ， インコーポレイテッド Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
EP4013402B1 (en) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2024137751A1 (en) * 2022-12-21 2024-06-27 Kura Oncology, Inc. Methods of treating advanced solid tumors
CN121175048A (zh) * 2023-05-09 2025-12-19 库拉肿瘤学公司 用法尼基转移酶抑制剂和pi3k抑制剂治疗鳞状细胞癌的方法
WO2025101691A1 (en) * 2023-11-08 2025-05-15 Exelixis, Inc. Methods for treating cancer using compounds that inhibit pkmyt1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EA000710B1 (ru) * 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2209066C2 (ru) * 1997-06-02 2003-07-27 Янссен Фармацевтика Н.В. Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы
HRP20000904A2 (en) * 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
EA200100766A1 (ru) * 1999-02-11 2002-02-28 Пфайзер Продактс Инк. Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов

Also Published As

Publication number Publication date
MXPA00011856A (es) 2002-06-04
PT1106612E (pt) 2004-06-30
DE60008206D1 (de) 2004-03-18
EP1106612A1 (en) 2001-06-13
DE60008206T2 (de) 2004-12-02
JP2001213876A (ja) 2001-08-07
TR200400342T4 (tr) 2004-03-22
EP1106612B1 (en) 2004-02-11
ES2212971T3 (es) 2004-08-16
ATE259365T1 (de) 2004-02-15
CA2327026A1 (en) 2001-05-30
US6596735B1 (en) 2003-07-22
DK1106612T3 (da) 2004-05-17

Similar Documents

Publication Publication Date Title
BR0005633A (pt) Derivados de quinolina úteis para inibição da farnesil proteìna transferase
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
ATE242231T1 (de) Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
PT928788E (pt) Compostos farmaceuticamente activos
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
HUP0101146A2 (hu) Foszfolipáz enzim inhibitor hatású indolszármazékok, valamint a vegyületeket tartalmazó gyógyászati készítmények
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ATE321038T1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
PT992509E (pt) Novos derivados macrolidos
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
YU49902A (sh) Supstituisani derivati piperazina kao mtp inhibitori
ATE219085T1 (de) 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5&lt;alfa&gt;-reduktaseinhibitorer
PT1351954E (pt) Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
HRP990130B1 (en) HALOGEN DERIVATIVES 9a-N-(N&#39;-ARYLCARBAMOYL)- AND 9a-N-(N&#39;-ARYLTHIOCARBAMOYL)-9-DEOXO-9a-AZA-9a OF HOMOERYTHROMYCIN A
DE69908855D1 (de) 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.